Original Article| Volume 24, ISSUE 8, P1755-1760, August 2015

Validation of the DRAGON Score in a Chinese Population to Predict Functional Outcome of Intravenous Thrombolysis–Treated Stroke Patients


      The DRAGON score predicts functional outcome of ischemic stroke patients treated with intravenous thrombolysis. Our aim was to evaluate its utility in a Chinese stroke population.


      Patients with acute ischemic stroke treated with intravenous thrombolysis were prospectively registered in the Thrombolysis Implementation and Monitor of acute ischemic Stroke in China. We excluded patients with basilar artery occlusion and missing data, leaving 970 eligible patients. We calculated the DRAGON score, and the clinical outcome was measured by the modified Rankin Scale at 3 months. Model discrimination was quantified by calculating the C statistic. Calibration was assessed using Pearson correlation coefficient.


      The C statistic was .73 (.70-.76) for good outcome and .75 (.70-.79) for miserable outcome. Proportions of patients with good outcome were 94%, 83%, 70%, and 0% for 0 to 1, 2, 3, and 8 to 10 score points, respectively. Proportions of patients with miserable outcome were 0%, 3%, 9%, and 50% for 0 to 1, 2, 3, and 8 to 10 points, respectively. There was high correlation between predicted and observed probability of 3-month favorable and miserable outcome in the external validation cohort (Pearson correlation coefficient, .98 and .98, respectively, both P < .0001).


      The DRAGON score showed good performance to predict functional outcome after tissue-type plasminogen activator treatment in the Chinese population. This study demonstrated the accuracy and usability of the DRAGON score in the Chinese population in daily practice.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Stroke and Cerebrovascular Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.
        N Engl J Med. 1995; 333: 1581-1587
        • Hacke W.
        • Kaste M.
        • Bluhmki E.
        • et al.
        Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.
        N Engl J Med. 2008; 359: 1317-1329
        • Saver J.L.
        Hemorrhage after thrombolytic therapy for stroke: the clinically relevant number needed to harm.
        Stroke. 2007; 38: 2279-2283
        • Strbian D.
        • Meretoja A.
        • Ahlhelm F.J.
        • et al.
        Predicting outcome of IV thrombolysis-treated ischemic stroke patients: the DRAGON score.
        Neurology. 2012; 78: 427-432
        • Stegmayr B.
        • Vinogradova T.
        • Malyutina S.
        • et al.
        Widening gap of stroke between east and west. Eight-year trends in occurrence and risk factors in Russia and Sweden.
        Stroke. 2000; 31: 2-8
        • Strbian D.
        • Seiffge D.J.
        • Breuer L.
        • et al.
        Validation of the DRAGON score in 12 stroke centers in anterior and posterior circulation.
        Stroke. 2013; 44: 2718-2721
        • Seiffge D.J.
        • Karagiannis A.
        • Strbian D.
        • et al.
        Simple variables predict miserable outcome after intravenous thrombolysis.
        Eur J Neurol. 2014; 21: 185-191
        • Whiteley W.N.
        • Thompson D.
        • Murray G.
        • et al.
        Targeting recombinant tissue-type plasminogen activator in acute ischemic stroke based on risk of intracranial hemorrhage or poor functional outcome: an analysis of the third international stroke trial.
        Stroke. 2014; 45: 1000-1006
        • Liao X.L.
        • Wang C.X.
        • Wang Y.L.
        • et al.
        Implementation and outcome of thrombolysis with alteplase 3 to 4.5 h after acute stroke in Chinese patients.
        CNS Neurosci Ther. 2013; 19: 43-47
        • Saposnik G.
        • Kapral M.K.
        • Liu Y.
        • et al.
        IScore: a risk score to predict death early after hospitalization for an acute ischemic stroke.
        Circulation. 2011; 123: 739-749
        • Saposnik G.
        • Demchuk A.
        • Tu J.V.
        • et al.
        The iScore predicts efficacy and risk of bleeding in the National Institute of Neurological Disorders and Stroke Tissue Plasminogen Activator Stroke Trial.
        J Stroke Cerebrovasc Dis. 2013; 22: 876-882
        • Menon B.K.
        • Saver J.L.
        • Prabhakaran S.
        • et al.
        Risk score for intracranial hemorrhage in patients with acute ischemic stroke treated with intravenous tissue-type plasminogen activator.
        Stroke. 2012; 43: 2293-2299
        • Mazya M.
        • Egido J.A.
        • Ford G.A.
        • et al.
        Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe Implementation of Treatments in Stroke (SITS) symptomatic intracerebral hemorrhage risk score.
        Stroke. 2012; 43: 1524-1531
        • Saposnik G.
        • Guzik A.K.
        • Reeves M.
        • et al.
        Stroke prognostication using age and NIH Stroke Scale: SPAN-100.
        Neurology. 2013; 80: 21-28
        • Cucchiara B.
        • Tanne D.
        • Levine S.R.
        • et al.
        A risk score to predict intracranial hemorrhage after recombinant tissue plasminogen activator for acute ischemic stroke.
        J Stroke Cerebrovasc Dis. 2008; 17: 331-333
        • Johnston K.C.
        • Wagner D.P.
        • Wang X.Q.
        • et al.
        Validation of an acute ischemic stroke model: does diffusion-weighted imaging lesion volume offer a clinically significant improvement in prediction of outcome?.
        Stroke. 2007; 38: 1820-1825
        • Lou M.
        • Safdar A.
        • Mehdiratta M.
        • et al.
        The HAT Score: a simple grading scale for predicting hemorrhage after thrombolysis.
        Neurology. 2008; 71: 1417-1423
        • Kent D.M.
        • Selker H.P.
        • Ruthazer R.
        • et al.
        The stroke-thrombolytic predictive instrument: a predictive instrument for intravenous thrombolysis in acute ischemic stroke.
        Stroke. 2006; 37: 2957-2962
        • Strbian D.
        • Engelter S.
        • Michel P.
        • et al.
        Symptomatic intracranial hemorrhage after stroke thrombolysis: the SEDAN score.
        Ann Neurol. 2012; 71: 634-641
        • Flint A.C.
        • Faigeles B.S.
        • Cullen S.P.
        • et al.
        THRIVE score predicts ischemic stroke outcomes and thrombolytic hemorrhage risk in VISTA.
        Stroke. 2013; 44: 3365-3369
        • Wang Y.
        • Liao X.
        • Zhao X.
        • et al.
        Using recombinant tissue plasminogen activator to treat acute ischemic stroke in China: analysis of the results from the Chinese National Stroke Registry (CNSR).
        Stroke. 2011; 42: 1658-1664